CD274 and hepatocellular carcinoma: Immune checkpoint inhibitors that target cytotoxic T lymphocyte protein 4 (CTLA-4), programmed death receptor 1 (PD-1) or its ligand (PD-L1) have appeared as a new class of active agents against HCC.